Header Logo

Connection

MARIA GRAMATGES to Child

Back to Details
This is a "connection" page, showing publications MARIA GRAMATGES has written about Child.
MARIA GRAMATGES
Connection Strength
1.116
Child
  1. Understanding and addressing race disparities in childhood cancer outcomes. Nat Rev Cancer. 2024 Feb; 24(2):91-92.
    View in: PubMed
    Score: 0.051
  2. Preferences for survivorship education and delivery among Latino and non-Latino childhood cancer survivors and caregivers. J Cancer Surviv. 2025 Apr; 19(2):518-525.
    View in: PubMed
    Score: 0.051
  3. Poverty and health equity in childhood leukemia. Blood. 2023 07 20; 142(3):211-212.
    View in: PubMed
    Score: 0.050
  4. Clinician perceptions of Passport for Care, a web-based clinical decision support tool for survivorship care plan delivery. Pediatr Blood Cancer. 2023 01; 70(1):e30070.
    View in: PubMed
    Score: 0.047
  5. Distribution and frequency of tyrosine kinase inhibitor-associated long-term complications in children with chronic myeloid leukemia. Pediatr Blood Cancer. 2022 09; 69(9):e29786.
    View in: PubMed
    Score: 0.046
  6. A report from the Leukemia Electronic Abstraction of Records Network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment. Haematologica. 2022 05 01; 107(5):1185-1188.
    View in: PubMed
    Score: 0.045
  7. Short NK- and Na?ve T-Cell Telomere Length Is Associated with Thyroid Cancer in Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev. 2022 02; 31(2):453-460.
    View in: PubMed
    Score: 0.044
  8. An evidence-based, risk-adapted algorithm for antifungal prophylaxis reduces risk for invasive mold infections in children with hematologic malignancies. Pediatr Blood Cancer. 2021 12; 68(12):e29228.
    View in: PubMed
    Score: 0.043
  9. The relationship between chronic health conditions and cognitive deficits in children, adolescents, and young adults with down syndrome: A systematic review. PLoS One. 2020; 15(9):e0239040.
    View in: PubMed
    Score: 0.041
  10. Early evidence of pulmonary dysfunction in survivors of childhood Hodgkin lymphoma. Leuk Lymphoma. 2020 10; 61(10):2419-2427.
    View in: PubMed
    Score: 0.040
  11. Clinical and functional characterization of telomerase variants in patients with pediatric acute myeloid leukemia/myelodysplastic syndrome. Leukemia. 2021 01; 35(1):269-273.
    View in: PubMed
    Score: 0.040
  12. Genetic variation in POT1 and risk of thyroid subsequent malignant neoplasm: A report from the Childhood Cancer Survivor Study. PLoS One. 2020; 15(2):e0228887.
    View in: PubMed
    Score: 0.039
  13. Incidence and predictors of treatment-related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020 02; 67(2):e28063.
    View in: PubMed
    Score: 0.038
  14. Evidence for Genetic Risk Contributing to Long-Term Adverse Treatment Effects in Childhood Cancer Survivors. Annu Rev Med. 2018 01 29; 69:247-262.
    View in: PubMed
    Score: 0.033
  15. Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia. Pediatr Blood Cancer. 2017 Sep; 64(9).
    View in: PubMed
    Score: 0.032
  16. Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group. J Clin Oncol. 2016 11 01; 34(31):3766-3772.
    View in: PubMed
    Score: 0.031
  17. Telomere content and risk of second malignant neoplasm in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Clin Cancer Res. 2014 Feb 15; 20(4):904-11.
    View in: PubMed
    Score: 0.025
  18. Predicting the 10-year risk of cardiomyopathy in long-term survivors of childhood cancer. Ann Oncol. 2025 Oct; 36(10):1203-1211.
    View in: PubMed
    Score: 0.014
  19. Prediction of methotrexate neurotoxicity using clinical, sociodemographic, and area-based information in children with acute lymphoblastic leukemia. Oncologist. 2025 Jun 04; 30(6).
    View in: PubMed
    Score: 0.014
  20. TTN and BAG3 in Cancer Therapy-Related Cardiomyopathy Among Long-Term Survivors of Childhood Cancer. JAMA Netw Open. 2025 06 02; 8(6):e2515793.
    View in: PubMed
    Score: 0.014
  21. Contributions of cancer treatment and genetic predisposition to risk of subsequent neoplasms in long-term survivors of childhood cancer: a report from the St Jude Lifetime Cohort and the Childhood Cancer Survivor Study. Lancet Oncol. 2025 Jun; 26(6):806-816.
    View in: PubMed
    Score: 0.014
  22. The Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers: A Review. JAMA Oncol. 2025 May 01; 11(5):544-553.
    View in: PubMed
    Score: 0.014
  23. A framework-based guide for adapting and implementing primary care-based pediatric interventions to the pediatric oncology setting: HPV PROTECT as an exemplar. Cancer. 2025 May 01; 131(9):e35857.
    View in: PubMed
    Score: 0.014
  24. Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025 Jan; 45(1):4-11.
    View in: PubMed
    Score: 0.014
  25. Invasive Candidiasis in Pediatric Hematologic Malignancy: Increased Risk of Dissemination With Candida tropicalis. Pediatr Infect Dis J. 2025 Jan 01; 44(1):58-63.
    View in: PubMed
    Score: 0.013
  26. Episodes of acute methotrexate-related neurotoxicity linked to compromised long-term neurocognitive function. Pediatr Blood Cancer. 2024 Sep; 71(9):e31169.
    View in: PubMed
    Score: 0.013
  27. Trans-Ancestral Genetic Risk Factors for Treatment-Related Type 2 Diabetes Mellitus in Survivors of Childhood Cancer. J Clin Oncol. 2024 Jul 01; 42(19):2306-2316.
    View in: PubMed
    Score: 0.013
  28. Household income and health-related quality of life in children receiving treatment for acute myeloid leukemia: Potential impact of selection bias in health equity research. Cancer Med. 2024 Apr; 13(7):e6966.
    View in: PubMed
    Score: 0.013
  29. Barriers to long-term follow-up in pediatric Hodgkin lymphoma survivors. Pediatr Blood Cancer. 2024 Apr; 71(4):e30855.
    View in: PubMed
    Score: 0.013
  30. Racial and ethnic disparities in acuity of presentation among children with newly diagnosed acute leukemia. Pediatr Blood Cancer. 2024 Jan; 71(1):e30726.
    View in: PubMed
    Score: 0.013
  31. Acute and chronic kidney injury during therapy for pediatric acute leukemia: A report from the Leukemia Electronic Abstraction of Records Network (LEARN). Pediatr Blood Cancer. 2023 Dec; 70(12):e30696.
    View in: PubMed
    Score: 0.013
  32. Child and family perceptions of satisfaction with neutropenia management in pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2023 08; 70(8):e30420.
    View in: PubMed
    Score: 0.012
  33. Ethnic disparities in childhood leukemia survival by border residence: A Texas population-based analysis. Cancer. 2023 04 15; 129(8):1276-1286.
    View in: PubMed
    Score: 0.012
  34. Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate. Cancer. 2023 04 15; 129(8):1287-1294.
    View in: PubMed
    Score: 0.012
  35. Germline Genetic and Treatment-Related Risk Factors for Diabetes Mellitus in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study and St Jude Lifetime Cohorts. JCO Precis Oncol. 2022 12; 6:e2200239.
    View in: PubMed
    Score: 0.012
  36. Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: Implications for adoptive cell therapy. Pediatr Blood Cancer. 2023 01; 70(1):e30062.
    View in: PubMed
    Score: 0.012
  37. Implementation of a provider-focused intervention for maximizing human papillomavirus (HPV) vaccine uptake in young cancer survivors receiving follow-up care in pediatric oncology practices: protocol for a cluster-randomized trial of the HPV PROTECT intervention. BMC Pediatr. 2022 09 12; 22(1):541.
    View in: PubMed
    Score: 0.012
  38. Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2022 12; 63(12):2948-2954.
    View in: PubMed
    Score: 0.012
  39. Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group. Lancet Haematol. 2022 Sep; 9(9):e678-e688.
    View in: PubMed
    Score: 0.012
  40. Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia. Infect Control Hosp Epidemiol. 2023 02; 44(2):222-229.
    View in: PubMed
    Score: 0.011
  41. Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia. JAMA Netw Open. 2021 10 01; 4(10):e2128385.
    View in: PubMed
    Score: 0.011
  42. Assessing the left atrium of childhood cancer survivors. Int J Cardiovasc Imaging. 2021 Jan; 37(1):155-162.
    View in: PubMed
    Score: 0.010
  43. Hispanic ethnicity is associated with prolonged clearance of high dose methotrexate and severe nephrotoxicity in children and adolescents with acute lymphoblastic leukemia. Leuk Lymphoma. 2020 11; 61(11):2771-2774.
    View in: PubMed
    Score: 0.010
  44. Improving reproducibility of left ventricular ejection fraction in pediatric oncology patients: less is more. Int J Cardiovasc Imaging. 2020 Oct; 36(10):1887-1895.
    View in: PubMed
    Score: 0.010
  45. Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment. Pediatr Blood Cancer. 2021 09; 68(9):e28315.
    View in: PubMed
    Score: 0.010
  46. Prevalence and Predictors of Frailty in Childhood Cancer Survivors and Siblings: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2020 01 20; 38(3):232-247.
    View in: PubMed
    Score: 0.010
  47. Survival disparities for second primary malignancies diagnosed among childhood cancer survivors: A population-based assessment. Cancer. 2019 10 15; 125(20):3623-3630.
    View in: PubMed
    Score: 0.009
  48. DNA methylation and obesity in survivors of pediatric acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. Genes Chromosomes Cancer. 2019 01; 58(1):52-59.
    View in: PubMed
    Score: 0.009
  49. Premature Physiologic Aging as a Paradigm for Understanding Increased Risk of Adverse Health Across the Lifespan of Survivors of Childhood Cancer. J Clin Oncol. 2018 07 20; 36(21):2206-2215.
    View in: PubMed
    Score: 0.009
  50. An overview of disparities in childhood cancer: Report on the Inaugural Symposium on Childhood Cancer Health Disparities, Houston, Texas, 2016. Pediatr Hematol Oncol. 2018 Mar; 35(2):95-110.
    View in: PubMed
    Score: 0.009
  51. Radiation pneumonitis in pediatric Hodgkin lymphoma patients receiving radiation therapy to the chest. Pract Radiat Oncol. 2018 Sep - Oct; 8(5):e364-e368.
    View in: PubMed
    Score: 0.008
  52. Identifying patient- and family-centered outcomes relevant to inpatient versus at-home management of neutropenia in children with acute myeloid leukemia. Pediatr Blood Cancer. 2018 04; 65(4).
    View in: PubMed
    Score: 0.008
  53. Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B acute lymphoblastic leukemia. Int J Clin Exp Pathol. 2014; 7(9):6225-30.
    View in: PubMed
    Score: 0.007
  54. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Sep; 59(3):468-74.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.